Praxis’s Relutrigine May Offer Hope For Rare, Deadly Childhood Epilepsies

With Phase II data in two rare forms of developmental and epileptic encephalopathy, Praxis is moving to produce registrational data while hoping longer term to treat a broader range of DEE patients.